Press release

Maxim Group initiates the coverage of the
CROSSJECT share with a BUY
recommendation and a target price of €4.00

Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the
specialty pharma company in advanced phases of development and registration for ZEPIZURE® in
adults, is informing about the recent initiation of coverage by Maxim Group, the US brokerage firm
dedicated to biopharmaceutical companies and other emerging growth and technology
companies.

In a first equity research report titled “A Robust Needle-Free Auto-Injector Platform for Emergency
Therapies”, Maxim Group’s Equity Research issued a first BUY recommendation on the CROSSJECT
share. The price of the CROSSJECT share on the 29th of May 2025, the date of issue of the research
report, was €1.77.

« We are excited by this first endorsement by a leading broker-dealer firm in the U.S. specialized in
emerging growth companies in life sciences. We look forward to fueling the North American investor
community with further positive developments in relation with the registration of ZEPIZURE® with the
FDA and with the rest of our pipeline », said Patrick ALEXANDRE, CEO of CROSSJECT.


About CROSSJECT

CROSSJECT SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharmaceuticals
company developing medicines for emergency situations harnessing its award-winning needle-
free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for
ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The
Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to
easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare
skin or even through clothing. The Company’s other products in development include mainly
solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency
indications.

* This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services;
Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031.


About Maxim Group

Maxim Group is a leading full-service investment bank, securities and wealth management firm
headquartered in Midtown Manhattan. Maxim Group was formed in 2002 as an independent and
100% employee-owned firm providing customized solutions to a diverse range of corporate clients,
institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer


1
with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board
(MSRB), and is a member of FINRA, SIPC, and NASDAQ.

***

For further information, please contact:




Investor Relations
investors@crossject.com




2